Overview

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of Yogliptin (as monotherapy) compared with placebo after 24 weeks, and the safety (up to 52 weeks) of Yogliptin in Chinese patients with Type 2 diabetes who are insufficient glycaemic control with diet and exercise.
Phase:
Phase 3
Details
Lead Sponsor:
Chengdu Easton Biopharmaceuticals Co,Ltd